Hepatitis C virus and hepatocellular carcinoma: carcinogenesis in the era of direct-acting antivirals
Chronic hepatitis C virus (HCV) infection is a major cause of hepatic fibrosis and cirrhosis, with a risk for the development of hepatocellular carcinoma (HCC). Although highly effective direct-acting antivirals (DAAs) are available, the incidence, morbidity, and mortality of HCV-associated HCC are...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
August 2024
|
| In: |
Current opinion in virology
Year: 2024, Volume: 67, Pages: 1-8 |
| ISSN: | 1879-6265 |
| DOI: | 10.1016/j.coviro.2024.101423 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.coviro.2024.101423 Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S1879625724000373 
|
| Author Notes: | Felix Fiehn, Claudia Beisel and Marco Binder |
| Summary: | Chronic hepatitis C virus (HCV) infection is a major cause of hepatic fibrosis and cirrhosis, with a risk for the development of hepatocellular carcinoma (HCC). Although highly effective direct-acting antivirals (DAAs) are available, the incidence, morbidity, and mortality of HCV-associated HCC are still high. This article reviews the current knowledge of the mechanisms of HCV-induced carcinogenesis with a special focus on those processes that continue after virus clearance and outlines implications for patient surveillance after DAA treatment. |
|---|---|
| Item Description: | Online verfügbar 25 June 2024, Version des Artikels 25 June 2024 Gesehen am 16.12.2024 |
| Physical Description: | Online Resource |
| ISSN: | 1879-6265 |
| DOI: | 10.1016/j.coviro.2024.101423 |